Avoid specimen validity, drug screen codes on same day except in rare cases

Why This Topic Matters

The topic matters because improper same-day reporting of related laboratory services has been a source of audit findings and denied claims. Understanding the article helps billing and compliance teams reduce claim risk and recognize when Medicare guidance treats specimen-validity-related testing as part of a broader service.

Article Sections

1. Medicare and OIG guidance on specimen validity testing

   Overview of federal guidance, audit findings, and the compliance concerns driving scrutiny of urine specimen validity reporting.

2. When separate reporting may be considered

   Discussion of the limited situations in which related testing may be ordered for diagnostic purposes and how that affects same-day reporting.

3. Example and related coding context

   A brief illustrative scenario and mention of the broader coding context surrounding urine drug testing and specimen validation.

4. Payer-level enforcement and resources

   Notes on Medicare contractor activity and references to external CMS and OIG resources for further review.